Answers are grounded in this paper and cite their sources.
We report a case of diffuse large B-cell lymphoma complicated by granulocyte colony-stimulating factor (G-CSF)-associated vasculitis following filgrastim administration. The vasculitis resolved with corticosteroid therapy, and maintenance treatment was continued long-term. During salvage chemotherapy for lymphoma relapse 14 months after the initial episode, G-CSF was reintroduced because of persistent myelosuppression. Filgrastim and pegfilgrastim were used in subsequent cycles without recurrence of vasculitis. This case suggests that G-CSF re-administration may be cautiously considered on an individual basis, particularly when vasculitis is well controlled with corticosteroids and a sufficient interval has elapsed. These findings may help guide individualized management in similar clinical situations.
No takes yet. Share an insight, caveat, or question.
Teshima et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: